Exploring a Novel Treatment for Generalized Anxiety Disorder
About 1 in 20 adults in the U.S. grapple with generalized anxiety disorder (GAD). For some, symptoms can be so severe that they may become isolated, hardly leaving their homes, and struggling to hold down jobs or cultivate meaningful relationships. Traditional medications often fall short in providing relief.
Dr. Jennifer Mitchell, a neuroscientist at UCSF, has been working on innovative therapies aimed at addressing issues like drug and alcohol addiction, PTSD, stress, anxiety, impulsivity, and depression. She believes a new treatment could offer more hope than conventional options. So far, this experimental medication has yielded some unexpected results.
What is this intriguing new approach? It involves a pharmaceutical form of LSD.
Understanding Generalized Anxiety Disorder
GAD is a chronic condition characterized by anxiety that often feels out of proportion to real-life events. It can significantly disrupt daily activities.
Individuals may face challenges with concentration, memory, and decision-making, making it difficult to find or keep a job and manage home responsibilities, including parenting. They might also experience secondary depression stemming from anxiety, feeling restless or easily fatigued. Fears about leaving home can arise, particularly related to situations that may feel overwhelming or humiliating.
The Difference Between GAD and Everyday Anxiety
A key feature of GAD is its physical manifestations. Ongoing worry can trigger the body’s fight-or-flight response, releasing stress hormones that lead to various physical symptoms. This might include muscle tension, rapid breathing, headaches, insomnia, and other issues related to the cardiovascular, respiratory, or gastrointestinal systems.
Typical Treatments for GAD
Standard treatments usually consist of medications like Zoloft and Paxil, which aim to boost and stabilize serotonin levels in the brain. These medications tend to reduce anxiety symptoms by an average of 1.25 points on a 56-point scale — a modest change that may not significantly help everyone.
Why Consider LSD?
LSD and other psychedelics hold considerable promise for altering mood and emotions, especially in a therapeutic context. This potential was noted in prior studies using Ecstasy for PTSD treatment.
The specific formulation for LSD being investigated is called MM120. Its main role appears to be encouraging neuroplasticity in the brain, which might help shift negative thought patterns and enhance communication between different brain areas, tackling the rigid thinking often associated with GAD.
How Effective is MM120?
In an earlier phase of research, highlighted in JAMA, a single dose of MM120 was assessed over 12 weeks with around 200 participants suffering from moderate to severe GAD. Results showed that the drug notably decreased symptoms — reducing them by five to six points on the anxiety scale, which could actually shift some cases from moderate to mild.
Side Effects Observed
Participants were closely monitored after taking the drug. Side effects tended to be mild to moderate, including hallucinations, nausea, visual distortions, and headaches. Notably, these side effects were more common at higher doses, which are not being used in ongoing treatment since they showed no added benefit. Nausea, a typical side effect of psychedelics, was mitigated by keeping participants to a light breakfast and providing preemptive anti-nausea medication.
Challenges in Recruiting Participants
Finding suitable individuals for the study has its hurdles. We’re specifically targeting those with moderate to severe GAD, often the very individuals who may feel most unable to participate. This irony poses a significant challenge. Participants are screened by experienced clinicians who assess both verbal and non-verbal cues, working to establish trust that encourages vulnerability and reflection.
Interested in Learning More About MM120 Trials?
If you want to know about participating in MM120 trials at UCSF and other locations in California, more information can be found through this link. Additional details on other MM120 trial sites are available here.
